However, as patients are told that the development and intensity of an exanthema are rather associated with a better prognosis, the withdrawing of EGFR inhibitors from cancer therapy can be perturbing for the respective patients (Stintzing et al. 2012). This evidence concerns the gene EGFR and cancer.